Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05574010




Registration number
NCT05574010
Ethics application status
Date submitted
7/10/2022
Date registered
10/10/2022
Date last updated
12/06/2024

Titles & IDs
Public title
A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)
Scientific title
A Phase 1B Open-label/Phase 2 Double-blind Placebo- Controlled Study for Pharmacodynamic (PD) Activity, Pharmacokinetics (PK), Safety, and Tolerability of KAN-101 In Patients With Celiac Disease (CeD)
Secondary ID [1] 0 0
KAN-101-02
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Celiac Disease 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Cohort 1 in Part A
Treatment: Drugs - Cohort 2 in Part A
Other interventions - Placebo: Group 1 in Part B and Part C
Treatment: Drugs - Group 2 in Part B and Part C
Treatment: Drugs - Group 3 in Part B and Part C
Treatment: Drugs - Group 4 in Part B and Part C

Experimental: Cohort 1 in Part A - All eligible Part A participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 1

Experimental: Cohort 2 in Part A - All eligible Part A participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 2

Placebo comparator: Group 1 in Part B and Part C - All eligible Part B and Part C participants will receive 3 intravenous (IV) infusions of placebo

Experimental: Group 2 in Part B and Part C - All eligible Part B and Part C participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 3

Experimental: Group 3 in Part B and Part C - All eligible Part B and Part C participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 4

Experimental: Group 4 in Part B and Part C - All eligible Part B and Part C participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 5


Treatment: Drugs: Cohort 1 in Part A
Dose 1 KAN-101 Intravenous (IV) infusion

Treatment: Drugs: Cohort 2 in Part A
Dose 2 KAN-101 Intravenous (IV) infusion

Other interventions: Placebo: Group 1 in Part B and Part C
Placebo Intravenous (IV) infusion

Treatment: Drugs: Group 2 in Part B and Part C
Dose 3 KAN-101 Intravenous (IV) infusion

Treatment: Drugs: Group 3 in Part B and Part C
Dose 4 KAN-101 Intravenous (IV) infusion

Treatment: Drugs: Group 4 in Part B and Part C
Dose 5 KAN-101 Intravenous (IV) infusion
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence and severity of TEAEs as assessed by common terminology criteria for adverse events (CTCAE) in Part A
Timepoint [1] 0 0
28 days
Primary outcome [2] 0 0
Change in magnitude of IL-2 response pre- and post-GC in peripheral blood in Part B
Timepoint [2] 0 0
Baseline to Day 15
Primary outcome [3] 0 0
Change in magnitude of IL-2 response pre- and post-GC in peripheral blood
Timepoint [3] 0 0
0 (pre-GC) and 4 hours post-GC on Day 15
Secondary outcome [1] 0 0
KAN-101 plasma exposure in Part A: AUCinf
Timepoint [1] 0 0
0 (pre-dose) and up to 7 hours post dose
Secondary outcome [2] 0 0
KAN-101 plasma exposure in Part A: AUClast
Timepoint [2] 0 0
0 (pre-dose) and up to 7 hours post dose
Secondary outcome [3] 0 0
KAN-101 plasma exposure in Part A: Cmax
Timepoint [3] 0 0
0 (pre-dose) and up to 7 hours post dose
Secondary outcome [4] 0 0
KAN-101 plasma exposure in Part A: Tmax
Timepoint [4] 0 0
0 (pre-dose) and up to 7 hours post dose
Secondary outcome [5] 0 0
KAN-101 plasma exposure in Part A: t½
Timepoint [5] 0 0
0 (pre-dose) and up to 7 hours post dose
Secondary outcome [6] 0 0
KAN-101 plasma exposure in Part B and Part C: AUCinf
Timepoint [6] 0 0
0 (pre-dose) and up to 4 hours post dose
Secondary outcome [7] 0 0
KAN-101 plasma exposure in Part B and Part C: AUClast
Timepoint [7] 0 0
0 (pre-dose) and up to 4 hours post dose
Secondary outcome [8] 0 0
KAN-101 plasma exposure in Part B and Part C: Cmax
Timepoint [8] 0 0
0 (pre-dose) and up to 4 hours post dose
Secondary outcome [9] 0 0
KAN-101 plasma exposure in Part B and Part C: Tmax
Timepoint [9] 0 0
0 (pre-dose) and up to 4 hours post dose
Secondary outcome [10] 0 0
KAN-101 plasma exposure in Part B and Part C: t½
Timepoint [10] 0 0
0 (pre-dose) and up to 4 hours post dose
Secondary outcome [11] 0 0
Incidence and severity of TEAE as assessed by the CTCAE in Part B and Part C.
Timepoint [11] 0 0
Week 52

Eligibility
Key inclusion criteria
* Previous diagnosis of celiac disease based on histology and positive celiac serology
* HLA-DQ2.5 genotype
* Gluten-free diet for at least 12 months
* Negative or weak positive for transglutaminase IgA and negative or weak positive for DGP-IgA/IgG during screening
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Refractory celiac disease
* HLA-DQ8 genotype
* Previous oral gluten challenge within 12 months
* Selective IgA deficiency
* Diagnosis of Type-1 diabetes
* Active gastrointestinal diseases
* History of dermatitis herpetiformis

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/11/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/12/2025
Actual
Sample size
Target
126
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA,VIC,WA
Recruitment hospital [1] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [2] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [3] 0 0
The Royal Melbourne Hospital - Parkville
Recruitment hospital [4] 0 0
St John of God Midland Public and Private Hospitals - Midland
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
3128 - Box Hill
Recruitment postcode(s) [3] 0 0
3050 - Parkville
Recruitment postcode(s) [4] 0 0
6056 - Midland
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Minnesota
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
Nebraska
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Tennessee
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Utah
Country [16] 0 0
New Zealand
State/province [16] 0 0
Auckland
Country [17] 0 0
New Zealand
State/province [17] 0 0
Bay Of Plenty
Country [18] 0 0
New Zealand
State/province [18] 0 0
Hawke's Bay
Country [19] 0 0
New Zealand
State/province [19] 0 0
Otago
Country [20] 0 0
New Zealand
State/province [20] 0 0
Wellington
Country [21] 0 0
New Zealand
State/province [21] 0 0
Hamilton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Pfizer
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participants with Celiac Disease (CeD).
Trial website
https://clinicaltrials.gov/study/NCT05574010
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
Anokion SA
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Kanyos Bio, Inc. (a wholly owned subsidiary of Anokion S.A.)
Address 0 0
Country 0 0
Phone 0 0
+1 857-320-6607
Fax 0 0
Email 0 0
clinicaltrials@anokion.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05574010